Compounded vs Brand-Name GLP-1: A Clear, Compliant Comparison
If you are comparing "compounded vs brand" online, you deserve a comparison that does not hide the regulatory difference or dress compounding up as a discount duplicate of a brand pen.
This page explains the difference neutrally, how clinicians may choose a path, and how Refuvia prices each route today. RESTORE · TRANSFORM · THRIVE starts with honesty.
What "brand-name GLP-1" means
FDA-approved products (for labeled indications) such as Wegovy and Ozempic (semaglutide) or Zepbound and Mounjaro (tirzepatide) have gone through FDA review for safety, effectiveness, and quality for their approved uses. Your clinician may prescribe brand-name therapy when appropriate. You then obtain medication through a pharmacy — often with insurance dynamics, cash-pay pharmacy pricing, or manufacturer programs depending on your situation.
What "compounded GLP-1" means
Compounding is the preparation of a medication by a licensed compounding pharmacy for an individual patient when a clinician determines that the patient's medical needs cannot be met by an FDA-approved drug. That is a clinical judgment, not a marketing slogan.
We do not:
- Claim compounded products are the "same" as brand or share an "exact same active pharmaceutical ingredient" framing as equivalence
- Market compounding as a cheaper substitute for the same thing
- Treat compounding as automatically appropriate or available without a clinician’s determination
Side-by-side (plain language)
| FDA-approved brand | Compounded | |
|---|---|---|
| Regulatory status | FDA-approved for labeled uses | Not FDA-approved; not FDA-reviewed for safety, effectiveness, or quality |
| Relationship to brand | The approved product | Not generic, not identical, not equivalent |
| Who decides | Clinician + your history | Clinician + your history; pharmacy prepares if appropriate |
| Typical Refuvia price path | $100/mo care fee; you pay pharmacy for med | All-inclusive starting $249/mo (sema) or $329/mo (tirz) when prescribed |
Dual cost paths at Refuvia
Compounded all-inclusive
- Semaglutide starting at $249/mo
- Tirzepatide starting at $329/mo
- Structured as currently marketed on weight-care pages (medication when prescribed + included care elements)
Higher doses may cost more.
Branded care path (confirmed)
- $100/mo flat clinical-management fee
- Patient pays pharmacy for brand medication
- Clinician may prescribe brand when appropriate; access depends on pharmacy/insurance realities
Your clinician discusses which path fits — you are not forced into one script.
How clinicians think about medical necessity
Examples of clinical considerations (not an exhaustive legal checklist): patient-specific needs that an available FDA-approved product does not meet; formulation or access issues evaluated case-by-case; contraindications and monitoring. The clinician decides.
Related pages
Start your free consultation
Explore whether physician-directed care is appropriate for you. A prescription is never guaranteed — your clinician decides.
Frequently asked questions
Is compounded GLP-1 a generic of Wegovy/Ozempic/Zepbound?
No. Compounded medications are not FDA-approved generics and are not equivalent to those brands.
Why do prices look lower on the compounded path?
Different product category, different fulfillment model, different inclusions. Lower sticker price is not proof of sameness or superiority.
Can I choose the brand path instead?
When clinically appropriate, yes — with a $100/mo care fee and brand medication paid at the pharmacy.
Can I use HSA/FSA?
Often for eligible expenses — confirm with your plan administrator.